uprosertib
Small moleculeexperimental
Clinical trial activity
11 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
8
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00920257)
Timeline
Indications
Mechanism of action
- Serine/threonine-protein kinase AKTINHIBITOR
Serine/threonine-protein kinase AKT inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2ccc(F)c(F)c2)oc1Cl- Mol. weight
- 429.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3137336 ↗
Also known as
- gsk2141795
- gsk2141795
- gsk2141795
- gsk2141795c
- gsk2141795c
- uprosertib
- uprosertib
- uprosertib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01989598 | Phase 2 | Oct 30, 2013 | National Cancer Institute (NCI), University of Toronto |
| NCT01979523 | Phase 2 | Oct 23, 2013 | Cornell University, National Cancer Institute (NCI) |
| NCT01964924 | Phase 2 | Oct 2, 2013 | GlaxoSmithKline, National Cancer Institute (NCI), Ohio State University |
| NCT01958112 | Phase 2 | Oct 1, 2013 | Harvard University, National Comprehensive Cancer Network, Novartis |
| NCT01907815 | Phase 2 | Oct 1, 2013 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT01935973 | Phase 2 | Sep 1, 2013 | National Cancer Institute (NCI), NRG Oncology |
| NCT01941927 | Phase 2 | Sep 1, 2013 | National Comprehensive Cancer Network, University of California, San Francisco |
| NCT01902173 | Phase 1/Phase 2 (Phase 2) | Jul 19, 2013 | GlaxoSmithKline, National Cancer Institute (NCI), Novartis, Southwest Oncology Group |
| NCT01266954 | Phase 1 | Jun 1, 2010 | GlaxoSmithKline |
| NCT01138085 | Phase 1 | May 1, 2010 | GlaxoSmithKline |
| NCT00920257 | Phase 1 | Jun 1, 2009 | GlaxoSmithKline |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 6 | 6 | 1 | 2013 |
| GlaxoSmithKline | For profit | 5 | 3 | 2 | 2009 |
| National Comprehensive Cancer Network | Academic/Hospital | 2 | 0 | 1 | 2013 |
| Novartis | For profit | 2 | 0 | 1 | 2013 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Ohio State University | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Southwest Oncology Group | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2013 |
12 organizations
Page 1 / 1